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Sexual Functioning after Treatment for Testicular
Cancer
Comparison of Treatment Modalities
BACKGROUND. This retrospective study evaluates changes in sexual functioningGrieteke Jonker-Pool, M.A.1,2
Jean P. van Basten, M.D.1 after treatment for testicular cancer and investigates whether there is a relationship
with different treatment modalities.Harald J. Hoekstra, M.D., Ph.D.1
Mels F. van Driel, M.D., Ph.D.3 METHODS. A self-reported questionnaire was sent to 337 men who had been treated
for testicular cancer at the University Hospital Groningen between 1977 and 1994.Dirk Th. Sleijfer, M.D., Ph.D.4
Heimen Schraffordt Koops, M.D., Ph.D.1 Medical information was obtained from the patient records.
RESULTS. A response was received from 287 men (85%); 264 patients were includedHarry B. M. van de Wiel, M.A., Ph.D.2
in this study (78%). The mean patient age at follow-up was 37.7 years (range, 17±71
1 Department of Surgical Oncology, University years). The mean follow-up period was 6.7 years (range, 0.25±18 years). Decrease in
Hospital Groningen, Groningen, The Nether- sexual functions was reported by 40% of patients (decrease in libido: 19%; arousal:
lands. 12% erection: 12.5%; orgasm: 19%; and ejaculation: 26%). Moreover, 23.5% of pa-
tients responding reported decreased sexual activity and 12.5% were dissatis®ed2 Department of Medical Psychology, University
Hospital Groningen, Groningen, The Nether- with their sexual functioning. Patients with Stage II±IV nonseminoma who had
lands. been treated with polychemotherapy (PCT) with or without resection of residual
retroperitoneal tumor mass (RRRTM) (PCT { RRRTM) reported a signi®cantly3 Department of Urology, University Hospital
Groningen, Groningen, The Netherlands. sharper decrease in sexual functioning than patients who had been followed with
a wait-and-see policy (W & S) (Stage I nonseminoma patients). It was noteworthy4 Department of Medical Oncology, University
that patients treated by PCT alone reported more sharply decreased sexual func-Hospital Groningen, Groningen, The Nether-
lands. tioning than patients treated by PCT / RRRTM. Patients treated by radiotherapy
(Stage I±IIA seminoma) did not report ®ndings signi®cantly different from the
W & S group.
CONCLUSIONS. Testicular cancer patients are at risk for reduced sexual functioning,
especially when treated by chemotherapy, with or without resection of residual
tumor. Although chemotherapy may in¯uence somatic aspects of sexual function-
ing, it appears that psychologic factors arising from the confrontation with testicu-
lar cancer play a strongly mediating (if not determining) role. Cancer 1997;80:454–
64. q 1997 American Cancer Society.
KEYWORDS: testis, testicular cancer, sexual functioning, sexuality, treatment, self-
report questionnaire.
Although testicular cancer is a rare form of cancer, there is anincreasing incidence in the industrialized countries and it is one
Supported by a grant from the Dutch Cancer
of the most common malignancies among young men.1,2 The tumorSociety (RUG 94-873).
is found chie¯y in young men between the ages of 25 and 35 years,
Address for reprints: Dr. H. J. Hoekstra, Univer- their most sexually active years. The incidence in the Netherlands is
sity Hospital Groningen, Department of Surgical 4.7 per 100.000 population.3 It is important to evaluate the extent to
Oncology, P.O. Box 30.001, 9700 RB Gron- which sexual and fertility problems occur, because nearly 90% of these
ingen, The Netherlands.
patients can (often after intensive treatment) be cured completely.4
Within the ®eld of oncology there is increasing attention beingReceived December 3, 1996; revision received
March 4, 1997; accepted March 31, 1997. paid to sexual problems resulting from illness and the associated
q 1997 American Cancer Society
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treatment modalities.5±10 In testicular cancer patients, can still occur even after castration.34,35 The exact con-
sequences of subnormal testosterone levels on orgasmmuch attention has been focused on the possible
physiologic consequences on overt sexual behavior and ejaculation are current topics of discussion.32,36,37
Radiotherapy (RT) may decrease Leydig cell function-(erection, coitus, and ejaculation). It is only during the
past decade that the evaluation of sexuality in terms ing in the remaining testicle38±40 or testosterone pro-
duction.41,42 Although the penile blood vessels lie out-of its more subjective aspects (libido, arousal, orgasm,
and satisfaction)11±13 have entered the discussion.14±22 side the radiation ®eld, erectile dysfunction may be
related to radiation damage to the small blood vesselsData on sexual functioning after treatment for tes-
ticular cancer vary widely and only a few studies ana- and nerves that regulate the penile blood supply.43±45
Polychemotherapy (PCT) may decrease testosteronelyzed the results of sexual functioning in connection
with the treatment applied.14,15,18±20,22,23 However, levels through Leydig cell damage within the re-
maining testicle,43 or by hyperprolactinemia.46 How-comparison of outcomes is dif®cult due to lack of con-
formity regarding treatment regimens, composition of ever, Leydig cell dysfunction probably is temporary.47
Erectile dysfunction may be related to PCT-inducedthe patient groups, and research questions in the vari-
ous studies. For example, in some studies, a major risk vascular damage.16,48±50 In addition, theoretically, de-
creased ejaculation, erectile dysfunction, or orgasmicfactor for sexual dysfunction was found to be irradia-
tion; 18±20,22 in others it was found to be chemother- dif®culties may also be related to PCT-induced periph-
eral neuropathy.16,49apy.15,23,24 Some studies assume that there are no dif-
ferences between different treatment groups.14,25 One In patients treated by resection of residual retro-
peritoneal tumor mass after PCT (PCT/RRRTM), 6±study found no differences between irradiated patients
when compared with patients under surveillance only, 30% reported ejaculatory disturbances.51±55 It is un-
known whether retrograde ejaculation has a negativebut found signi®cant differences when these same pa-
tients were compared with healthy controls,20 whereas in¯uence on the intensity of orgasm.56 In the case of
reduced orgasmic intensity in patients treated by PCTin another study there were no signi®cant differences
between patients under surveillance and healthy con- and RRRTM, it is most likely not the retrograde ejacu-
lation, but PCT that is responsible.24,57 Because thetrols.26 Therefore, it is not quite clear whether and to
what extent physiologic consequences of a particular parasympathetic nerve tracts that regulate erection lie
outside the area of RRRTM, the same may be true intreatment, or emotional and cognitive consequences,
in¯uence sexual functioning. the case of erectile disturbances after PCT/RRRTM.
To gain better insight into possible changes in the
subjective experience of sexuality after testicular can-
METHODScer, as well as the in¯uence of various treatment mo-
Patients and Treatmentsdalities, a study was performed on patients who were
All patients who had been treated for a malignant tes-treated for testicular cancer at the University Hospital
ticular germ cell tumor between 1977±1994 at the Uni-Groningen between 1977±1994. In this study, the fol-
versity Hospital Groningen and who were still alive,lowing two questions played a central role: 1) To what
were approached by means of a written questionnaireextent does testicular cancer and/or its treatment lead
(n  337). The patients were informed about the useto changes in sexual functioning; and 2) To what extent
of the data by a cover letter wherein it was emphasizedare there differences in sexual functioning after treat-
that nonresponse would not affect treatment. On ament between the various treatment groups.
separate form patients could indicate whether they
wished to receive information about the results of theTreatment-Related Biologic-Organic Influences on Sexual
study. Permission to perform the study had been ob-Functioning
tained from the Medical Ethical Committee.To examine the extent to which biologic-organic as-
Two histologic types of testicular tumor were dis-pects relevant to sexual functioning may become dis-
tinguished: seminoma (ST) and nonseminomatousturbed after treatments for testicular cancer, an exten-
germ cell tumors (NSGCT); ST is generally diagnosedsive search of the literature was performed on the pos-
at a later age (40±50 years) than NSGCT. Patients weresible hormonal, vascular, or neurologic changes.27
staged according to the Royal Marsden Hospital Stag-After unilateral orchidectomy, decreased testos-
ing Classi®cation,58 as follows: Stage I: no metastasesterone levels were found in 5±34% of patients, proba-
evident outside testis; Stage II: infradiaphragmaticbly due to preexisting abnormalities in the remaining
lymph node metastasis (IIA:  2 cm; IIB: 2±5 cm;testicle.28±31 However, normal sexual functioning is
and IIC: 5 cm); Stage III: supradiaphragmatic lymphpossible even with very low serum testosterone levels
(6±12 nmol/L),32,33 and it has been shown that erection node metastases (A, B, and C, as for Stage II); and Stage
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IV: extranodal metastases (abdominal status same as Scoring
Changes in sexual response functions and sexual satis-for Stage II).
faction could be indicated on a 4-point scale (score ofAll patients underwent orchidectomy. Patients
0: ``no change at all'' to score of 3: ``sharp decrease'').with Stage I NSGCT were treated by orchidectomy
Ejaculatory problems could be indicated as early, late,alone and entered an intense outpatient follow-up
decreased, or completely absent. Changes in sexualpolicy (``Wait & See'' [W&S]), which was comprised
activity were measured by combining the questionsof physical check-ups, screening for elevated tumor
on sexual activity before the diagnosis and currently;markers, and computed tomography scanning.59 Pa-
in this way, a 7-point scale was obtained, from ``sharptients with metastasized NSGCT (Stage II±IV) received
decrease''(score of 03) to ``sharp increase''(score offour induction courses of PCT: cisplatin in combina-
/3). Changes in the value of sexuality could be indi-tion with vinblastine and bleomycin (PVB), or with
cated on a 5-point scale, from ``has become far lessetoposide rather than vinblastine (BEP).60 At the Uni-
important''(score of 02) to ``has become much moreversity Hospital Groningen, PCT has been used since
important'' (score of /2).1976.61,62 If there was any residual retroperitoneal tu-
mor tissue, surgical resection was subsequently under-
Statistical Analysistaken.53,63 Patients with Stage I or IIA ST received RT
To portray the clinical relevance of the results in inter-in a dose of 25±30 grays (Gy) to the ipsilateral paraaor-
pretive percentages, the raw scores for the above-men-tal and parailiac lymph nodes.64,65 Patients with Stage
tioned dependent variables were combined. Four-IIB±IV ST also received four courses of PVB or BEP,
point scales were dichotomized into two categories:but without additional surgical intervention.
scores 0 and 1 (no change and slight change), and
scores 2 and 3 (moderate change and sharp change)
Design were taken together. Because premature or retarded
From a medical point of view, treatment with the ejaculation was indicated by only 13 patients (5%) the
W&S approach is not as far-reaching as that within results of these items are described brie¯y, but not
the other treatment approaches; after orchidectomy, used in analyses. To obtain comparable outcomes, re-
the patients only have to attend regular outpatient duced ejaculation was scored as 2 and complete ab-
sence was scored as 3. Variables for which the patientcheck-ups. Therefore, to evaluate the possible in¯u-
was asked to indicate the amount of change were re-ence of the treatment modality (RT, PCT, or
duced to three categories: decrease, no change, andPCT/RRRTM), the W&S group formed a very accept-
increase in the relevant aspect.able control group.
To present the average outcomes of the various
scales in a comparable manner, the raw scores were
Questionnaire standardized on a scale from 0 to 10. To analyze the
Because there were no adequate validated question- differences between the various treatment groups,
naires available, a questionnaire was designed in means and standard deviations (SD) of the raw scores
which patients could indicate the extent to which they were used (chi square- or Mann-Whitney U test for
felt their sexual functioning had changed after treat- categoric variables, and Student's t or analysis of vari-
ment for testicular cancer. Questions concerned: de- ance [ANOVA] for continuous variables.) A P value ¡
crease of sexual response (libido, sexual arousal, erec- 0.05 was considered to be signi®cant. Correlations
tion, and orgasm) decrease, absence, retarded, or pre- were calculated using Spearman's Rho.
mature ejaculation; decrease in sexual satisfaction;
changes in sexual activities; and changes in the value RESULTS
of sexuality because of testicular cancer and its treat- Response
ment. The questionnaire was returned by 287 patients (re-
In addition, there were questions regarding demo- sponse rate, 85%). Those who did not have complete
graphic variables (age, relationship, education, reli- medical data (n 9; 2.7%), or who underwent no stan-
gion, and work) and patients were asked if there were dard treatment (n 5; 1.5%), or had bilateral testicular
any other physical abnormalities besides testicular cancer (n  9; 2.7%) were excluded. A total of 264
cancer. The questionnaire comprised a total of 31 patients (78%) remained for further analysis.
items. Data on the independent variables (tumor type:
NSGCT/ST, and treatment [W&S, RT, PCT, and Patient Characteristics
PCT/RRRTM]) were obtained from the medical re- Table 1 provides an overview of the patient character-
istics (n  264; 78%). There were no signi®cant differ-cords.
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TABLE 1
Patient and Treatment Characteristics (n  264)
Total W & S RT PCT PCT / RRRTM
(n  264) (n  59) (n  41) (n  42) (n  122) Significant
(100%) (22.5%) (15.5%) (16%) (46%) P value
Age, yrs (SD) 37.7 (9.7) 34.2 (9.8) 43.4 (10.5) 38.9 (9.8) 36.9 (8.5) 0.0001a
Follow-up, yrs (SD) 6.7 (4.4) 4.4 (3.2) 3.8 (2.2) 7.1 (3.5) 8.7 (4.6) 0.0000a
Partner (%)
No 28 (10.5) 5 (8.5) 5 (12) 5 (12) 13 (11)
Yes 236 (89.5) 54 (91.5) 36 (88) 37 (88) 109 (89) NSb
Work (%)
No 21 (8) 5 (8.5) 7 (17.5) 2 (5) 7 (5.5)
Yes 219 (83) 49 (83) 28 (68) 35 (83) 107 (88)
Other 24 (9) 5 (8.5) 6 (14.5) 5 (12) 8 (6.5) NSb
Education (%)
Lower 64 (24) 17 (29) 10 (24.5) 9 (21.5) 28 (23)
Middle 133 (50.5) 28 (47) 16 (39) 28 (66.5) 61 (50)
High 67 (25.5) 14 (24) 15 (36.5) 5 (12) 33 (27) NSb
Religion (%)
No 161 (61) 42 (71) 28 (68) 24 (57) 67 (55) NSb
Yes 103 (39) 17 (29) 13 (32) 18 (43) 55 (45)
Other diseases (%)
No 216 (82) 53 (90) 32 (78) 32 (76) 99 (81) NSb
Yes 48 (18) 6 (10) 9 (22) 10 (24) 23 (19)
W & S: intensive regular outpatient check-ups (Wait & See); RT: radiotherapy; PCT: polychemotherapy; RRRTM: resection of residual retroperitoneal tumor mass; NS: not signi®cant; SD: standard deviation.
a Determined by analysis of variance.
b Determined by chi-square test; NS where P  0.05.
ences in mean age and mean follow-up between indi- tween the 4 treatment groups with regard to these
and other demographic variables. Other diseases inviduals included and not included (n  23; 6.8%) and
nonrespondent patients (n  27; 8%) Of a total of 264 addition to testicular cancer were reported by 48 pa-
tients (18%); there were no signi®cant differences be-patients, 59 had Stage I NSGCT with the W&S policy
(22.5%), 41 had ST and were followed by 25±30 Gy tween the 4 treatment groups, although the W&S
group reported the fewest number of patients withadjuvant RT(15.5%), 42 had a disseminated NSGCT
and were treated by PCT (16%), and another 122 PCT other diseases (n  6; 10%) than the other groups (RT:
n  9; 22%; PCT: n  10; 24%; and PCT/RRRTM: n patients received adjuvant surgery (PCT/RRRTM;
46%). At the time of the study, the mean age of the 23; 19%). The diseases most frequently mentioned by
the patients were: back pain (four times), stomachtotal patient group was 37.7 years (range, 17±71 years;
SD, 9.7 years). The mean age of the patients treated complaints (four times), Peyronie's disease (two
times), cardiac problems (two times), and general fa-with RT (all ST) was 43.4 years, which was 9 years older
than the mean age of the W&S group (34.2 years). The tigue (two times).
four treatment groups differed signi®cantly in mean
age (P  0.0001). The mean follow-up period was 6.7 Changes in Sexual Functioning in the Total Patient Group
Table 2 provides information about the reported inci-years (range, 0.25±17.7 years; SD, 4.4 years); the 4
groups differed signi®cantly on this aspect (P  dence of posttreatment decreased sexual response (libido
[a], arousal [b], erection [c], and orgasm [d]), decreased0.0000). The mean follow-up period in the W&S group
(4.4 years) was much shorter compared with the PCT ejaculation (e), and sexual dissatisfaction (f), as well as
changes in sexual activity (g) and the value of sexualitygroup (7.1 years) and the PCT/RRRTM group (8.7
years). This can be explained by the fact that approxi- (h). Libido loss was reported by 51 patients (19%), reduced
arousal by 32 (12%), reduced erection by 33 (12.5%), andmately 25% of patients originally in the W&S group
developed metastases during follow-up and subse- reduced orgasm by 50 (19%). Retarded ejaculation was
mentioned by only one patient from the PCT/RRRTMquently received PCT.59 The majority of patients had
a partner (n  236; 89.5%) and were employed (n  group, premature ejaculation was reported overall by 12
patients (total group: 4.5%: W&S: 5%; RT: 5%; PCT: 7%;219; 83%), there were no signi®cant differences be-
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TABLE 2
Changes in Sexual Functioning (Raw Scores Classified into Percentages) (n  264)
Total W & S RT PCT PCT / RRRTM
(n  264) (n  59) (n  41) (n  42) (n  122)
No. (%) No. (%) No. (%) No. (%) No. (%)
a. Libido decreased 51 (19) 7 (12) 9 (22) 13 (29.5) 23 (19)
b. Arousal decreased 32 (12) 3 (5) 7 (17) 6 (14.5) 16 (13)
c. Erection decreased 33 (12.5) 2 (3.5) 6 (14.5) 7 (17) 18 (15)
d. Orgasm decreased 50 (19) 7 (12) 6 (14.5) 12 (28.5) 25 (20.5)
e. Ejaculate: decreased 37 (14) 4 (7) 6 (14.5) 9 (21.5) 18 (15)
Absent 31 (12) Ð Ð Ð 31 (25.5)
Total 68 (26) 4 (7) 6 (14.5) 9 (21.5) 49 (40.5)
Total decrease a±d 77 (29) 11 (19) 11 (27.5) 18 (43) 37 (30.5)
Decrease a±e 106 (40) 13 (22.5) 12 (30) 19 (45) 63 (52)
f. Satisfaction decreased 33 (12.5) 3 (5) 3 (7.5) 6 (14.5) 15 (12)
g. Sexual activity
Decreased 62 (23.5) 6 (10) 9 (22) 15 (36) 32 (26)
Increased 27 (10.5) 11 (19) 2 (5) 2 (5) 12 (10)
Total change 89 (34) 17 (29) 11 (27) 17 (41) 44 (36)
h. Value of sexuality
Decreased 19 (7) 2 (3.5) 3 (7.5) 4 (10) 11 (9)
Increased 39 (15) 11 (19) 4 (10) 5 (12) 19 (15.5)
Total change 58 (22) 13 (22.5) 7 (17.5) 9 (22) 30 (24.5)
W&S: intensive regular outpatient check-ups (Wait & See); RT: radiotherapy; PCT: polychemotherapy; RRRTM: resection of residual retroperitoneal tumor mass.
and PCT/RRRTM: 3.5%). Due to the low incidence of ally higher than those of the W&S group, but only the
scores for sexual activity were signi®cantly different. Inthese problems, they were not analyzed any further. A
decrease or absence of ejaculation was reported by 68 the group treated by PCT, the scores were considerably
higher than those in the W&S group; signi®cant differ-patients (26%); complete absence was mentioned exclu-
sively by patients treated by PCT/RRRTM. A total of 77 ences were found for almost all variables using the
nonparametric tests, but application of ANOVA cor-patients reported a reduction of ¢1 aspects (a±d) of the
sexual response (29%) (ejaculation included 106 patients rected for age showed signi®cant differences only for
decreased libido, orgasm, ejaculation, and for the[40%] reporting reduction of ¢1 functions). Thirty-three
patients (12.5%) were dissatis®ed about their sexual life index of the cumulative scores and changes in sexu-
al activity. The scores in the group treated bysince treatment. This mainly concerned patients who re-
ported reduction of¢2 sexual functions (16 patients, 49% PCT/RRRTM were generally much higher than those
in the W&S group; it was surprising that on all pointsof this group). 34% of the patients reported a change in
sexual activity (n  89; decrease: 23.5%, increase: 10.5%). the scores in this group were lower than those in the
PCT group. After correction for age, differences be-Changes in the value of sexuality were reported by 22%
(n  58: decrease: 7.5%, increase: 15%). In addition to tween this group and the W&S group were signi®cant
for ejaculation, the index of the cumulative scores,outcomes of the total population, Table 2 also provides
an overview of the outcomes per treatment modality. sexual dissatisfaction, and changes in sexual activity.
In addition, ejaculation in this group differed signi®-
cantly from that in the RT and PCT groups (vs. RT: PComparison of the Various Treatment Groups  0.000; vs. PCT: P  0.002; data not shown).Table 3a presents the results of a comparison between
the W&S group versus the other treatment modalities
(RT, PCT, and PCT/RRRTM). Due to the fairly wide Correlation between Dependent Variables and
Covariablesvariation in mean age between the various treatment
groups, not only the Mann-Whitney U test was used, The correlation between the scores for the sexual re-
sponse functions (libido, arousal, erection, and or-but also ANOVA corrected for age. In Table 3b the
standardized mean scores of the various treatment gasm) was fairly high and these variables form a homo-
geneous scale (Spearman's Rho: 0.55±0.74; Cron-modalities are presented.
The scores in the group treated by RT were gener- bach's a: 0.89), whereas the correlation between these
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TABLE 3a
Differences in Sexual Functioning Depending on Treatment: ‘‘Wait & See’’ (n  59) versus RT (n  41), PCT (n  42), and PCT / RRRTM (n  122)
W & S Corr. W & S Corr. W & S vs. Corr.
PCT / RRRTMa vs. RTa ageb vs. PCTa ageb PCT / RRRTMa ageb
a. Libido NSc NS 0.019 0.033 0.036 NS
b. Arousal NS NS 0.035 NS 0.042 NS
c. Erection NS NS 0.056 NS NS NS
d. Orgasm NS NS 0.010 0.014 NS NS
e. Ejaculate NS NS 0.031 0.04 0.000 0.000
Index a-d NS NS 0.006 0.017 0.012 0.047
Index a±e NS NS 0.004 0.004 0.000 0.001
f. Satisfaction NS NS 0.041 NS 0.020 0.041
g. Sexual
activity 0.016 NS 0.001 0.005 0.006 0.023
h. Value of
sexuality NS NS NS NS NS NS
W&S: intensive regular outpatient check-ups (Wait & See); RT: radiotherapy; Corr.: corrected for age; PCT: polychemotherapy; RRRTM: resection of residual retroperitoneal tumor mass; NS: not signi®cant.
a Determined using the Mann±Whitney u test.
b Analysis of variance corrected for age.
c All nonsigni®cant values were P  0.05.
TABLE 3b
Means of the Raw Scores (Standardized into a Scale 0–10) for Sexual Functioning per Treatment group (n  264)
Total PCT /
mean (SD) W & S RT PCT RRRTM
a. Libido 02.31 (2.95) 01.47 02.44 03.02 02.43
b. Arousal 01.59 (2.58) 00.90 01.71 01.98 01.75
c. Erection 01.45 (2.82) 00.73 01.67 01.87 01.58
d. Orgasm 02.17 (3.22) 01.44 01.54 03.17 02.38
e. Ejaculate 02.17 (3.69) 00.45 00.98 01.43 03.55
Index a-d 01.90 (2.53) 01.15 01.88 02.56 02.04
Index a-e 01.95 (2.39) 01.01 01.67 02.34 02.35
f. Satisfaction 01.78 (2.85) 01.07 01.38 02.14 02.13
g. Sexual activity 00.24 (1.30) /0.26 00.33 00.60 00.33
h. Value of sexuality /0.18 (1.17) /0.38 /0.06 /0.06 /0.17
SD: standard deviation; W & S: intensive regular outpatient check-ups (Wait & See); RT: radiotherapy; PCT: polychemotherapy; RRRTM: resection of residual retroperitoneal tumor mass; /: increase; 0: decrease.
variables and ejaculation, and the item-total correla- was not signi®cant or very low (Spearman's Rho: 0.12±
0.23) (Table 4a). Although there were signi®cant differ-tion of ejaculation was rather low and decreased the
Cronbach's a (Spearman's Rho: 0.22±0.33; item-total ences in age and follow-up period between the four
treatment groups (Table 1), these variables, as well ascorrelation: 0.37; Cronbach's a: 0.84). Sexual satisfac-
tion showed a reasonably strong correlation with the the stage of the disease and the presence of other
complaints or diseases, showed only weak correlationsscores for the sexual response functions: libido,
arousal, erection, and orgasm (Spearman's Rho: 0.56± with the scores for reduced sexual functioning (Spear-
man's Rho:  0.12±0.31) (Table 4b).0.62), but the correlation with decreased ejaculation
was less strong (Spearman's Rho: 0.43). Changes in
sexual activity showed a moderate correlation with the DISCUSSION
This large-scale study on 337 patients (total response:sexual response functions (libido, arousal, erection,
and orgasm) (Spearman's Rho: 0.40±0.48) and a low n  287, 85%; included patients: n  264, 78%) pro-
vides information about changes in sexual functioningcorrelation with ejaculation (Spearman's Rho: 0.20).
The correlation with changes in the value of sexuality after treatment for testicular cancer as perceived by
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TABLE 4a
Correlation between Sexual Variables (Spearman’s Rho P  0.05) (n  264)
Li Ar Er Or Ej Sa Act Value
a. Libido 1.00
b. Arousal 0.74 1.00
c. Erection 0.55 0.71 1.00
d. Orgasm 0.58 0.65 0.67 1.00
e. Ejaculate 0.29 0.22 0.33 0.32 1.00
f. Satisfaction 0.56 0.56 0.58 0.62 0.43 1.00
g. Sexual activity 0.48 0.48 0.40 0.41 0.20 0.41
h. Value 0.23 0.20 NSa NS NS 0.24 NS
Index a±d 0.87 0.83 0.75 0.84 0.34 0.66 00.48 NS
Index a±e 0.81 0.76 0.72 0.79 0.61 0.69 00.46 NS
Li: libido; Ar: arousal; Er: erection; Or: orgasm; Ej: ejaculate; Sa: satisfaction; Act: sexual activity; NS: not signi®cant.
a All nonsigni®cant avlues were Spearman's Rho P  0.12.
TABLE 4b and only partly supported conclusions of previous re-
Correlation between Sexual Variables and Covariables (Spearman’s search on physiologic aspects,27 as well as conclusions
Rho P  0.05) (n  264) of earlier studies comparing treatments.14±15,18±20,22±23
In absolute terms, the W&S patients reported the leastOther
decrease in sexual functions and sexual activity. Al-Age Follow-up Stage diseases
though comorbidity does not apply to the W&S group,
a. Libido 0.19 NSa 0.14 0.21 22.5% of these patients nevertheless reported a de-
b. Arousal 0.27 0.16 0.12 0.16
crease of ¢1 sexual functions. These ®ndings appearc. Erection 0.30 0.14 NS 0.21
to be somewhat different from those derived from re-d. Orgasm 0.15 0.12 0.16 NS
search in healthy respondents, although no exact ®g-e. Ejaculate NS 0.21 0.31 0.18
f. Satisfaction 0.19 0.21 0.16 0.25 ures are available regarding disturbances in sexual
g. Sexual activity 0.26 NS 0.17 0.16 functioning for the normal population. 66,67 It is dif®-
h. Value of sexuality 0.25 NS NS NS
cult to explain this result on the basis of biologic-or-Index a±d 0.23 0.13 0.18 0.20
ganic disturbances, because orchidectomy was theIndex a±e 0.27 0.20 0.26 0.22
only medical interference. Emotional or cognitive fac-
a All nonsigni®cant values were Spearman's Rho P  0.12. tors, such as anxiety, impairment of physical integrity,
feelings of loss, aversions, and loss of control, may
play an important role.6,14,17,20±22 The fact that approxi-
mately 25% of patients with Stage I disease treatedthe patients. It shows how the subjective appraisal of
with surveillance can be expected to recur and requiresexuality can be in¯uenced by testicular cancer. Nearly
chemotherapy59 may also generate anxiety and stress.25% of the patients reported decreased sexual activity
For this reason, it has been argued that patients should(23.5%), whereas 29% reported a decrease in ¢1 as-
be offered the option of initial nerve-sparing retroperi-pects of male sexual response (libido, arousal, erec-
toneal lymph node dissection (RPLND) versus surveil-tion, and orgasm). Decreased libido and orgasm were
lance.68,69 However, it appears that doctors tend toreported relatively more frequently than decreased
overestimate the psychologic morbidity and underes-arousal and erection. When ejaculation was included,
timate the experienced physical complaints of testicu-40% of respondents reported a decrease in ¢1 sexual
lar cancer patients, in particular patients treated byfunctions. There was a moderate correlation between
W&S,70 although the eventual psychosomatic compo-sexual dissatisfaction and a decrease in sexual re-
nent of these complaints remains unclear.sponse functions. Approximately 50% of the patients
The RT group was an average of 9 years olderwho reported a decrease in ¢2 sexual functions were
that the W&S group, but the 2 groups did not differdissatis®ed. Compared with the situation prior to diag-
signi®cantly in any aspect except decreased sexual ac-nosis and treatment, nearly 25% of patients stated that
tivity. Correlations between sexual functioning andthe value of their sexuality had changed.
age were generally weak and correction of the scoresComparison of treatment modalities introduced
important nuancing to the results of the total group, for age did not change the general trend. Erectile dys-
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function due to RT-induced vascular damage appears appear to have an inhibitory in¯uence on sexual func-
tioning,76,77 although this relation also may occur inunlikely because only a few RT patients reported erec-
tile problems (14.5%). A large proportion of the RT reverse.78 In addition, negative ®xation on the genital
region can lead to a decrease in sexual activity.79 Asgroup mentioned decreased libido and sexual activity
(22% each). It is unlikely that these problems were in patients with gynecologic cancers,80 changes in the
experience of sexuality and sexual behavior in patientscaused by low testosterone levels because generally
measurements of serum testosterone are within the treated for testicular cancer can only partly be ex-
plained by biologic-organic disturbances. Althoughnormal ranges,42 and even very low serum testosterone
levels permit normal sexual functioning.32,33 In this re- patients receiving PCT are at risk for sexual morbidity,
changes in sexual functioning appear to be stronglyspect, emotional and cognitive factors also may be
decisive. related to emotional, cognitive, and motivational as-
pects.11,56,81,82 In this respect, it was noteworthy that aIn the group treated by PCT ({RRRTM) a limited
number of patients reported erectile problems (17% decrease in one or more sexual functions led to re-
duced sexual satisfaction in only a limited number ofand 15%, respectively), and there was no statistic sig-
ni®cant difference compared with the W&S group. patients.14 It is possible that after a cancer diagnosis,
which carries a heavy emotional burden and involvesTherefore, PCT-induced erectile dysfunction could not
be proven. However, a considerable proportion of PCT a life-threatening experience, patients rebalance their
emotions and cognitions, such as norms and valuespatients reported decreased libido (29.5%) and orgasm
(28.5%). In addition, after correction for age, this group concerning sexuality and the partner relation-
ship.15,18,21 This may give rise to shifts in their out-still differed signi®cantly from the W&S group. Theo-
retically, these differences may have been caused by look.83,84
long term biologic impacts of PCT such as neuropathy
and general health status, but at the same time inter-
CONCLUSIONSaction with emotional and cognitive factors may have
A substantial proportion of the patients treated forplayed a decisive role in view of the life-threatening
testicular cancer in the current study experiencednature of cancer in general and the drastic nature of
a decrease in sexual functioning, although the ma-PCT.15,16,23 The same applies to the decrease in sexual
jority reported no symptoms at all. Comparisonsactivity, as was reported by nearly 25% of the patients.
between treatment groups introduced importantFor a patient undergoing a course of PCT, the situation
nuancing to the results and showed signi®cant dif-is more or less impossible to control because of the
ferences between patient groups. Patients treatedparadoxic nature of this aggressive treatment, and the
by PCT ({RRRTM) reported a considerably sharperpatient's unclear future. Such massive loss of control
decrease in sexual functions, satisfaction, and ac-can give rise to passivity71 and perhaps even to emo-
tivity than the W&S group. Therefore, chemother-tional regression.72
apy can be considered to be the main risk factor forAccording to expectations,73±75 the sharpest de-
a decrease in sexual functioning.crease in ejaculation was reported in the PCT/RRRTM
The differences between treatment groups ingroup. This group was the only one that reported ab-
reduction of sexual functions could not be attrib-sence of ejaculation, e.g., retrograde ejaculation. How-
uted to age, the duration of follow-up, tumor stage,ever, contrary to expectations, considerably less de-
or the presence of other diseases, because thesecrease in libido, orgasm, and sexual activity was re-
variables showed only very weak correlations withported (although the differences were not statistically
the variables concerning sexuality. Furthermore,signi®cant) in the group treated by PCT/RRRTM than
there were no differences in demographic variablesin the group treated by PCT alone. This trend under-
or reports of other abnormalities between the treat-scores the lack of evidence for a mere biologic-organic-
ment groups. Theoretically, treatment-related bio-based decrease in sexual functioning after treatment
logic-organic factors, such as hormonal, vascular,by PCT. From a psychologic point of view, chemother-
or neurogenic disturbances, may be held responsi-apy may give rise to uncertainty, anxiety, and passivity,
ble for reduced sexual functioning, but this has yetwhereas additional resection of residual tumor mass
to be demonstrated. Psychologic factors appear toafter chemotherapy (PCT / RRRTM) may increase
play an important mediating (if not determining)feelings of recovery and certainty by its concrete effect.
role. If future studies con®rm this theory, psy-This same argument has been stated with respect to
chologic intervention would be of bene®t for pa-the discussion concerning nerve-sparing RPLND ver-
tients with decreased sexual functioning after treat-sus surveillance in Stage I NSGCT.70
In general, uncertainty, anxiety, and loss of control ment for testicular cancer.
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